Table 3 High and low distributions of each of the three measured VEGFs (8 groups)

From: Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC

t/VEGF-A/VEGF121/VEGF165

Overall (n = 149)

EGFR-WT (n = 114)

High/high/high

54

44

High/high/low

11

8

High/low/high

7

3

High/low/low

3

2

Low/high/high

0

0

Low/high/low

8

5

Low/low/high

15

10

Low/low/low

51

42

Back to article page